Our data suggest that SNX10 deficiency enhanced CMA-mediated degradation of targeted proteins to increase specific amino acids, and subsequently activated mTORC1 to facilitate the tumor progression (Fig. 7). The gene discussed is SNX10; the disease is neoplasm.